Bromide

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Mai 9, 2024

LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update.

Key Points: 
  • PDUFA Target Action Date for Ensifentrine of June 26, 2024
    Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
    LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update.
  • If approved, the Company intends to launch ensifentrine in the US market in the third quarter of 2024.
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 2:00 p.m. BST on Thursday, May 9, 2024, to discuss the first quarter 2024 financial results and the corporate update.
  • An electronic copy of the first quarter 2024 results press release will also be made available today on the Company’s website.

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Februar 29, 2024

LONDON and RALEIGH, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2023, and provides a corporate update.

Key Points: 
  • The debt facility provides non-dilutive capital and further financial flexibility to support Verona Pharma’s continued growth, including the commercialization of ensifentrine.
  • Net loss: Net loss was $14.1 million for the fourth quarter ended December 31, 2023 (Q4 2022: net loss $10.5 million).
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EST / 2:00 p.m. GMT on Thursday, February 29, 2024, to discuss the fourth quarter and full year 2023 financial results and the corporate update.
  • An electronic copy of the fourth quarter and full year 2023 results press release will also be made available today on the Company’s website.

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Sugammadex Mylan, sugammadex, Date of authorisation: 15/11/2021, Revision: 3, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024

Human medicines European public assessment report (EPAR): Sugammadex Mylan, sugammadex, Date of authorisation: 15/11/2021, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Sugammadex Mylan, sugammadex, Date of authorisation: 15/11/2021, Revision: 3, Status: Authorised

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, November 2, 2023

LONDON and RALEIGH, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2023, and provides a corporate update.

Key Points: 
  • PDUFA Target Action Date of June 26, 2024
    Conference call today at 9:00 a.m. EDT / 1:00 p.m. GMT
    LONDON and RALEIGH, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2023, and provides a corporate update.
  • Net loss: Net loss was $14.7 million for the third quarter ended September 30, 2023 (Q3 2022: $15.6 million).
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 1:00 p.m. GMT on Thursday, November 2, 2023, to discuss the third quarter 2023 financial results and the corporate update.
  • An electronic copy of the third quarter 2023 results press release will also be made available today on the Company’s website.

Explainer: the philosophy of Jean-Jacques Rousseau is profoundly contemporary

Retrieved on: 
Montag, September 25, 2023

No account of the modern era – not just modern thought – could ignore him.

Key Points: 
  • No account of the modern era – not just modern thought – could ignore him.
  • But like any major thinker, there are risks in summaries – some of which give us clues about Rousseau himself.
  • Although he is known as a social and political philosopher, Rousseau’s creative output does not resemble that of a contemporary “theorist”.
  • These are now conventional tropes, but they were only emerging at the time Rousseau was writing.

Natural or artificial

    • Rousseau had shot to fame a decade earlier, after winning an essay competition advertised in the literary magazine Mercure de France.
    • Where much philosophical discussion had been centred around the distinction between the “natural” and the “supernatural”, Rousseau opposed the natural to the artificial.
    • He argued that what we ordinarily think of as civilisational progress creates – and then aims to satisfy – new and artificial vices, serving our vanity and not our natural needs.
    • In fact, he proposed there were many good reasons to think they were greater in both.
    • Read more:
      Guide to the Classics: Voltaire’s Candide — a darkly satirical tale of human folly in times of crisis

Society and inequality

    • Developing these ideas, in 1754, Rousseau wrote his Discourse on the Origin and Basis of Inequality Among Men.
    • In it, he attempted a thought experiment which imagined what humans may have been like in a “pre-civilisational” state.
    • Rousseau was aware that this act of imagination was speculative and he could not be sure of its results.
    • He held that inequality was artificial.

Education and politics

    • The first was the institution of a new kind of education; the second was reorienting politics towards a new moral foundation.
    • In Émile, or On Education (1862), Rousseau wrote a treatise on education in the form of a bildungsroman – the first and likely the last of its kind.
    • He sought to outline the conditions of a good education, which he thought should be based on lived experience and the development of individual character, not rote learning, mechanical memorisation, or even the reading of books.
    • As for moral education, young people should learn about the consequences of their actions.
    • Rousseau’s terminology has oriented discussions of morality, self-development and politics from the 18th century to the counterculture of the 1960s, the New Age movement of the 1980s, and beyond.

Deism and human nature

    • According to Rousseau, we know what we know of God from Nature and Reason alone.
    • In Rousseau, Judge of Jean-Jacques (1776), Rousseau addresses this question directly, and in typically Rousseauian fashion:
      whence could the painter and apologist of human nature have taken his model, if not from his own heart?
    • He has described this nature just as he felt it within himself.
    • whence could the painter and apologist of human nature have taken his model, if not from his own heart?
    • He has described this nature just as he felt it within himself.

Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Mittwoch, August 16, 2023

MALVERN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) --  Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”), is a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced results for the three and six months ended June 30, 2023 and provided a business update.

Key Points: 
  • “Our second quarter was a transformative period for Baudax Bio, during which we announced positive top-line results from our Phase 2 BX1000 trial and capped off with our acquisition of TeraImmune,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio.
  • The acquisition was unanimously approved by the Board of Directors of Baudax Bio and the Board of Directors of TeraImmune.
  • Financial Results for the Three Months Ended June 30, 2023
    As of June 30, 2023, Baudax Bio had cash and cash equivalents of $1.4 million.
  • Baudax Bio reported net loss from continuing operations of $(14.7) million, or $(4.08) per share, for the six months ended June 30, 2023.

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Retrieved on: 
Montag, Juni 12, 2023

"With two medications in one ready-to-use syringe, PREVDUO™ reduces complexity and increases efficiency for hospitals and healthcare providers."

Key Points: 
  • "With two medications in one ready-to-use syringe, PREVDUO™ reduces complexity and increases efficiency for hospitals and healthcare providers."
  • Both neostigmine methylsulfate and glycopyrrolate have been approved in the U.S. as single, active ingredient drug products.
  • Neostigmine is always administered in conjunction with glycopyrrolate and, until now, its administration has required two syringes.
  • This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error—all of which support quality patient care.

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Retrieved on: 
Montag, Juni 12, 2023

"With two medications in one ready-to-use syringe, PREVDUO™ reduces complexity and increases efficiency for hospitals and healthcare providers."

Key Points: 
  • "With two medications in one ready-to-use syringe, PREVDUO™ reduces complexity and increases efficiency for hospitals and healthcare providers."
  • Both neostigmine methylsulfate and glycopyrrolate have been approved in the U.S. as single, active ingredient drug products.
  • Neostigmine is always administered in conjunction with glycopyrrolate and, until now, its administration has required two syringes.
  • This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error—all of which support quality patient care.